MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.atherosclerosis.2023.117312

Медицинская библиотека · Atherosclerosis · 2023

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.

Raja Vikrama, Aguiar Carlos, Alsayed Nasreen, Chibber Yogeyaa S, ElBadawi Hussein, Ezhov Marat, Hermans Michel P, Pandey Ramesh Chandra, Ray Kausik K, Tokgözoglu Lale, Zambon Alberto, Berrou Jean-Pascal, Farnier Michel

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Dyslipidemia refers to unhealthy changes in blood lipid composition and is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Usually, low-density lipoprotein-cholesterol (LDL-C) is the primary goal for dyslipidemia management. However, non-high-density lipoprotein cholesterol (non-HDL-C) has gained attention as an alternative, reliable goal. It encompasses all plasma lipoproteins like LDL, triglyceride-rich lipoproteins (TRL), TRL-remnants, and lipoprotein a [Lp(a)] except high-density lipoproteins (HDL). In addition to LDL-C, several other constituents of non-HDL-C have been reported to be atherogenic, aiding the pathophysiology of atherosclerosis. They are acknowledged as contributors to residual ASCVD risk that exists in patients on statin therapy with controlled LDL-C levels. Therefore, non-HDL-C is now considered an independent risk factor or predictor for CVD. The popularity of non-HDL-C is attributed to its ease of estimation and non-dependency on fasting status. It is also better at predicting ASCVD risk in patients on statin therapy, and/or in those with obesity, diabetes, and metabolic disorders. In addition, large follow-up studies have reported that individuals with higher baseline non-HDL-C at a younger age (<45 years) were more prone to adverse CVD events at an older age, suggesting a predictive ability of non-HDL-C over the long term. Consequently, non-HDL-C is recommended as a secondary goal for dyslipidemia management by most international guidelines. Intriguingly, geographical patterns in recent epidemiological studies showed remarkably high non-HDL-C attributable mortality in high-risk countries. This review highlights the independent role of non-HDL-C in ASCVD pathogenesis and prognosis. In addition, the need for a country-specific approach to dyslipidemia management at the community/population level is discussed. Overall, non-HDL-C can become a co-primary or primary goal in dyslipidemia management.

Для цитирования: Raja Vikrama, Aguiar Carlos, Alsayed Nasreen, Chibber Yogeyaa S, ElBadawi Hussein, Ezhov Marat, Hermans Michel P, Pandey Ramesh Chandra, Ray Kausik K, Tokgözoglu Lale, Zambon Alberto, Berrou Jean-Pascal, Farnier Michel. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.. Atherosclerosis. 2023. DOI: 10.1016/j.atherosclerosis.2023.117312.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.